Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI

Why It Matters

Sustained reductions in hard endpoints validate imaging‑guided PCI as a cost‑effective strategy for complex coronary disease, prompting broader adoption to improve long‑term patient outcomes. The data also shape future guideline updates and reimbursement policies worldwide.

Key Takeaways

• Intravascular imaging cuts 5‑year target lesion failure by 30%.
• Benefit strongest in chronic total occlusions and long diffuse lesions.
• Imaging guidance cuts cardiac death risk over 50% versus angiography.
• Adoption limited by cost, reimbursement, and operator familiarity.
• Guidelines grant class I indication for imaging‑guided PCI.

Pulse Analysis

Intravascular imaging has moved from a niche tool to a cornerstone of complex percutaneous coronary intervention (PCI) after the RENOVATE‑COMPLEX‑PCI trial demonstrated durable benefits at five years. The study enrolled 1,639 patients with high‑risk lesion subsets—chronic total occlusions, long diffuse plaques, and bifurcations—and showed a 32% relative reduction in target‑lesion failure and a striking 53% drop in cardiac death when operators used imaging to guide stent placement. These outcomes underscore how precise plaque assessment and stent optimization at the index procedure can mitigate restenosis and thrombosis, delivering long‑term survival gains.

The clinical advantage aligns with recent guideline shifts: both European (2018) and U.S. (2021) revascularization recommendations now assign a class I, level A indication to intravascular imaging for complex PCI. Yet real‑world adoption lags, primarily because of higher procedural costs, variable reimbursement structures, and a learning curve for interventionalists. Hospitals that prioritize imaging for lesions most likely to alter strategy—such as chronic total occlusions—can achieve the greatest return on investment, balancing upfront expenses against downstream reductions in repeat revascularizations and hospital readmissions.

Looking ahead, the trial’s findings set the stage for next‑generation studies like FRAME‑AMI2, which will compare imaging‑guided versus physiology‑guided approaches in multivessel acute myocardial infarction. As evidence accumulates and health‑system economics evolve, insurers are expected to broaden coverage, and training programs will embed imaging proficiency into core curricula. The convergence of robust data, guideline endorsement, and emerging reimbursement models suggests that intravascular imaging will become standard practice for complex PCI, reshaping the economics and outcomes of coronary care.